Nifurtimox-Eflornithine Combination Therapy for Second-stage Gambiense Human African Trypanosomiasis: Médecins Sans Frontières experience in the Democratic Republic of the Congo
AffiliationDivision of International and Humanitarian Medicine, University Hospitals of Geneva, Switzerland. firstname.lastname@example.org
MetadataShow full item record
JournalClinical Infectious Diseases
AbstractExisting diagnostic and treatment tools for human African trypanosomiasis (HAT) are limited. The recent development of nifurtimox-eflornithine combination therapy (NECT) has brought new hopes for patients in the second stage. While NECT has been rolled out in most endemic countries, safety data are scarce and derive only from clinical trials. The World Health Organization (WHO) coordinates a pharmacovigilance program to collect additional data on NECT safety and efficacy. We report here the results of 18 months of experience of NECT use in treatment centers run by Médecins Sans Frontières in the Democratic Republic of the Congo (DRC).
PublisherOxford University Press
DescriptionTo access this article, click on "Additional Links"